MYnd Analytics (NASDAQ:MYND), a behavioral health company with tools and technologies aimed at improving the delivery of mental health services through the combination of telemedicine and data analytics, announced it has received its first notice of patent allowance in Europe on the Company’s neuromodulation platform for predicting patients likely to respond to Transcranial Magnetic Stimulation (TMS).
The patent has as its subject matter the Company’s proprietary process and proprietary outcome data on the use of individualized Quantitative EEG (QEEG) features to predict non-response of individuals to TMS therapy. Although depression is the dominant indication for TMS today, the FDA recently cleared a migraine/pain indication, and a deep-TMS protocol for obsessive compulsive disorder (OCD). TMS-derived interventions are also being developed and tested for Alzheimer’s and anxiety.
Key Quote: “The business potential for predicting patients likely to respond to TMS is significant, as the TMS market is growing; the global neuromodulation market is growing at 11% annually to an estimated $13 billion by 2024.” George Carpenter, MYnd’s President and Chief Innovation Officer
The Backstory: MYnd Analytics (NASDAQ:MYND), with its wholly owned subsidiary Arcadian Telepsychiatry Services LLC, is a technology-enabled telepsychiatry and teletherapy company that provides enhanced access to behavioral health services, improves patient outcomes and helps lower the costs associated with behavioral health issues. The MYnd Psychiatric EEG Evaluation Registry (PEER) is a predictive analytics decision support tool that helps physicians reduce trial and error treatment for behavioral health conditions. PEER provides the physician a personalized care plan with recommended treatment options based on a patient’s unique brain markers, reducing treatment time and treatment costs. Arcadian Telepsychiatry Services LLC provides a suite of complementary telemedicine services that can be combined with PEER, including telepsychiatry, teletherapy, digital patient screening, curbside consultation, on-demand services, and scheduled encounters for all age groups. MYnd’s customers include major health plans, health systems, and community-based organizations. To read more about the benefits of this patented technology for patients, physicians and payers, please visit: www.myndanalytics.com.
MYnd Analytics (NASDAQ: MYND), will host an investor webinar and live Q and A session Thursday, April 4, 2019 at 11 am Eastern/8 am Pacific.
The webinar will feature a presentation by Patrick Herguth, Chief Executive Officer of MYND, and Robin L. Smith, Chairman of the Board. The executives will discuss the competitive positioning of MYND, the Company's growth opportunities, value proposition, and more. Following the presentation, Mr. Herguth and Ms. Smith will take questions from attendees.
Disclosure
MYnd Analytics, Inc. (NASDAQ: MYND) is a client of RedChip Companies, Inc. MYND agreed to pay RedChip Companies, Inc. a monthly cash fee for RedChip investor awareness services.
Small-cap stocks have outperformed large-caps over the past decade, and Wall Street and its institutional clients are paying more attention to the asset class than they used to. According to research by Eduardo Lecubarri, global head of small- and mid-cap equity strategy at JPMorgan, small-caps have seen both their analyst coverage and portfolio weights rise in recent years.
The small-cap Russell 2000 index has climbed 255% since 2009, 11 percentage points ahead of the S&P 500.
Chemisis International (CSE: CSI; OTCQB: CADMF) announced an agreement to acquire 19.9% of GSRX Industries (OTCQB: GSRX).
Why It Matters: Chemesis has extensive manufacturing, processing and extraction capabilities, which tie together with GSRX's ability to professionally operate dispensaries and CBD stores. This will greatly expand Chemesis' footprint in strategic locations, specifically Puerto Rico, California, Tennessee and Texas for both THC and hemp based non-THC CBD products. As part of the Agreement, GSRX has granted Chemesis a right of first refusal to manufacture GSRX's current and future production requirements in all jurisdictions where Chemesis has production capabilities that will meet the demand of its location and product growth. GSRX also will ensure that there is dedicated shelf space for Chemesis' brands and products at each GSRX licensed THC dispensary and CBD store.
Key Quote: "We are very pleased to complete this share exchange which will provide increased financial strength to both companies. With the exchange, GSRX ensures an ongoing, quality supply chain for its growing family of dispensaries, while Chemesis is guaranteed retail distribution access in key markets that only GSRX can provide. Both companies win, and our shareholders benefit from this alliance as well.” Les Ball, CEO
Disclosure
GSRX Industries (OTCQB: GSRX) is a client of RedChip Companies. RedChip Companies, Inc. received 1,000,000 registered shares of GSRX for consulting services. Be advised RedChip intends to sell some or all of its shares at any time, including when you are buying.
Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, provided a shareholder update last week, following the Company’s recent shareholder meeting held in late March.
Key Quote: “We continue to make significant progress towards completion of our CE Mark. We are working closely with our designated European Notified Body, British Standards Institute (BSI), a global leader in accreditation services, on a Fast Track application.” – Dr. Faz Chowdhury, CEO
What’s Next: The outlook for NMRD is extremely encouraging and company management is confident it will secure regulatory approval in the foreseeable future. Moreover, the global addressable market for CGM is estimated at $82 billion per year, and over $13 billion in the U.S. alone. NMRD’s product includes significant and unique features that the competition does not provide, in particular the non-invasive nature of the device and the flexible wear period. These advantages should allow SugarBEAT® to become adopted by a very large and diverse patient and user group, thus driving shareholder value.
Disclosure
Nemaura Medical (NASDAQ: NMRD) is a client of RedChip Companies. NMRD agreed to pay RedChip a monthly cash fee for investor awareness services.
Cuentas (OTCQB: CUEN), a Financial Technology (FinTech) service provider delivering mobile banking, online banking, prepaid debit and digital content services to unbanked, underbanked and underserved communities, announced today that it is now selling Sony PlayStation, Microsoft Xbox Live and Nexon Karma digital content at its 31,600+ bodega locations in the US.
Why It Matters: Cuentas has now integrated its digital content system with the Black011 portal to sell prepaid digital products including, but not limited to, Sony PlayStation, Microsoft Xbox and Nexon Karma prepaid gaming products through the SDI Next distribution network of over 31,600 “bodega” retailers. Bodegas are typically single owner markets, gas stations and local stores that serve many immigrant and urban neighborhoods.These services and products are available through the www.black011.com intranet portal that is available in these Bodegas.
Key Quote: “We are enthusiastic about working to sell these products at our more than 31,600 locations and through the Cuentas App. These products should provide extra revenue for the retailers and should increase visits to these bodegas.” – Arik Maimon, Founder and CEO
What’s Next: Cuentas is preparing to launch 15 additional major prepaid digital content brands in the near future as well as the Cuentas Mobile App and Mobile Wallet during 2019.
Cuentas (OTCQB: CUEN), will host a group call Thursday, April 4, 2019, at 4 pm Eastern / 1 pm Pacific.
To join the call, which will not be archived, please phone Craig Brelsford at (407) 571-0902, or [email protected]. Craig will give you the number to the conference line and the password.
The group call will feature a presentation by Michael De Prado, Founder, President, COO, and Director of Cuentas. Mr. De Prado will discuss recent developments and key upcoming milestones.
Disclosure
Cuentas (OTCQB: CUEN) agreed to pay RedChip Companies, Inc. 10,000 shares of Rule 144 stock and a monthly cash fee for three (3) months of investor relation awareness services.
• Digital Ally has asserted two significant patent infringement lawsuits involving Axon and WatchGuard that have had significant impacts on quarterly results primarily due to the timing and amounts of legal fees expended on such lawsuits
• The Pretrial Order further notes that Digital Ally is seeking “reasonable royalty damages … as a result of TASER’s infringement of the ‘452 Patent from February 2, 2016 through August 17, 2018 [of] $68,456,524” and that “[p]rior to trial in this matter, Digital Ally will supplement its damages calculations”
• Revenue decreased to approximately $11.3 million in 2018 from approximately $14.6 million in 2017, a 23% decline. Revenue in fourth quarter 2018 decreased to approximately $2.4 million from approximately $2.9 million in the same period in 2017. The primary reasons for the revenue decrease in the fourth quarter 2018 and for the 2018 fiscal year are that DGLY continues to face increased challenges for its in-car and body-worn systems as its competitors have released new products with more advanced features compared to DGLY’s and have maintained their extreme product price cuts
• Digital Ally is concentrating on expanding its recurring service revenue to help stabilize revenues on a quarterly basis. Revenues from cloud storage have been increasing in recent quarters and increased to $694,000 for 2018 compared to $279,000 for 2017, an increase of $415,000, or 149%
Key Quote: “We continue to expand our recurring service-based revenue to help stabilize and grow our revenues on a quarterly basis. Additionally, we plan to introduce a new product platform, the EVO-HD, designed specifically for in-car systems in 2019 to address our competitors’ new product features. This new product platform will utilize advanced chipsets that will generate new and highly advanced products for our law enforcement and commercial customers.” Stanton E. Ross, Chief Executive Officer of Digital Ally, Inc.
The Backstory: Digital Ally, Inc., headquartered in Lenexa, KS, specializes in the design and manufacture of the highest quality video recording equipment and video analytic software. Digital Ally pushes the boundaries of technology in industries such as law enforcement, emergency management, commercial fleets, and consumer use. Digital Ally’s complete product solutions include in-car and body cameras, cloud and local management software, and automatic recording technology. These products work seamlessly together and are simple to install and operate. Digital Ally products are sold by domestic direct sales representatives and international distributors worldwide.
Disclosure
Digital Ally, Inc. (NASDAQ: DGLY) is a client of RedChip Companies, Inc. DGLY agreed to pay RedChip Companies, Inc., a monthly cash fee for four (4) months of RedChip investor awareness services.
• Total revenue for the three months ended December 31, 2018, was CAD$141,901, compared to revenue of CAD$109,103 in the same year-ago quarter. Total revenue in 2018 was CAD$777,302 compared with CAD$109,173 in 2017. The increase in revenue was due to the full year of revenue from the Intermeccanica acquisition in 2017.
• Commenced production of the SOLO electric vehicle at the Zongshen production facility in Chongqing, China. In the first quarter of 2019, the Company produced 20 single passenger SOLO electric vehicles, which have been shipped to North America
• Hosted a grand opening ceremony of the Zongshen SOLO electric vehicle production facility in Chongqing, China, with attendance from the Electra Meccanica Executive Team, Board of Directors, Zongshen Chairman, Zongshen Senior Executive Management, Zongshen factory management and the Canadian and United States Consuls General.
• Opened first Electra Meccanica dealership in Los Angeles, California to facilitate test drives, maintenance and SOLO electric vehicle deliveries to the strategic U.S. market
Key Quote: “Our state-of-the-art production facility in Chongqing, China with our strategic partner, Zongshen Industrial Group, is in the process of ramping up towards mass production. We produced 20 SOLO EV’s in the first quarter of 2019 and remain fully confident in our ability to ramp up production and start to deliver SOLO’s to our customers in 2019.” Jerry Kroll, CEO of Electra Meccanica
The Backstory: Electra Meccanica is a designer and manufacturer of electric vehicles. The Company builds the innovative, all-electric SOLO, a single passenger vehicle developed to revolutionize the way people commute, as well as the Tofino, an elegant high-performance two seater electric roadster sports car. Both vehicles are tuned for the ultimate driving experience while making your commute more efficient, cost-effective and environmentally friendly. Intermeccanica, a subsidiary of Electra Meccanica, has successfully been building high-end specialty cars for 60 years. For more information, visit www.electrameccanica.com.
• Scilex expects SP-102 to be the first FDA approved non-opioid epidural injections for sciatica with the potential to replace the current 10 to 11 million off-label epidural steroid injections administered each year in the U.S.
• Complete Enrollment of Phase 2 Trial to Characterize the Pharmacodynamics and Safety of Repeat Dose SP-102 Administered by Epidural Injection in Subjects with Lumbosacral Radiculopathy, a.k.a. sciatica
• All subjects experienced rapid reduction of leg and back pain following two SP-102 injection treatments, with group median for average pain in affected leg reduced over 50% throughout 28 days for each injection (100% response rate). There were no serious adverse events observed
• The current pivotal Phase 3 trial (fast track status) is proceeding as planned and has already reached near 50% enrollment completion
Key Quote: “We believe these Phase 2 data validate our novel program and bolster our confidence that SP-102 can provide radicular pain/sciatica patients with persistent and prolonged pain relief. Lumbar radicular pain, otherwise known as sciatica, is commonly treated by off-label epidural steroid injections,” said Jaisim Shah, President and Chief Executive Officer of Scilex Holdings
The Backstory: Scilex Holding Company, a majority-owned subsidiary of Sorrento located in San Diego, California, responsibly develops and brings branded products to market using technologies designed to maximize quality of life for the patients it serves. We are uncompromising in our focus to become the global pharmaceutical leader in pain management through social, environmental, economic and ethical principles. Scilex’s product, ZTlido® (lidocaine topical system 1.8%), is a branded lidocaine topical system formulation for the treatment of relieving the pain of post-herpetic neuralgia, also referred to as after-shingles pain. For more information, visit www.scilexpharma.com.
Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases. Sorrento's multimodal multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (“G-MAB™ library”), clinical stage immuno-cellular therapies (“CAR-T”), intracellular targeting antibodies (“iTAbs”), antibody-drug conjugates (“ADC”), and clinical stage oncolytic virus (“Seprehvir®”).
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on small-cap and mid-cap companies. Since 1992, RedChip has delivered concrete, measurable results for its clients through the most comprehensive service platform in the industry for small-cap and mid-cap companies. These services include a worldwide distribution network for its stock research written by analysts holding the CFA designation; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated over 2.3 million unique investor views; quarterly global online institutional and retail investor conferences that reach over 10,000 investors annually; "The RedChip Money Report" television show which airs in 100 million homes across the U.S. on The Family Channel; a weekly newsletter delivered to 60,000 investors; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that the RedChip Companies Inc. is an investor relations firm hired by certain Companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and view RedChip’s Disclosures.
